Exact, CMS to Discuss Coverage of Colon Cancer Test That FDA Deemed ‘Adulterated’ | GenomeWeb
Three months after the US Food and Drug Administration said Exact Sciences’ genetic colorectal cancer screening test is “adulterated” and “misbranded,” the company will meet with the Centers for Medicare & Medicaid Services to discuss its request for the federal government to reimburse for the test.
Exact plans to meet with CMS later this week about the status of its application for a national coverage decision for the PreGen-Plus assay, a stool-based DNA colorectal cancer screening test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.